Tyson Purdy, MD
Family Medicine · Lubbock, TXNPI 1346402328
Payments from drug & device makers
Across 119 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$470
- Lilly USA, LLC$246
- Pfizer$198
- Takeda Pharmaceuticals U.S.A., Inc.$151
- AstraZeneca$141
- GSK$110
- plus $797 from 26 others
What the payments were for
- Food & beverage$2,08299%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $470 |
| Lilly USA, LLC | 16 | $246 |
| Pfizer | 10 | $198 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $151 |
| AstraZeneca | 9 | $141 |
| GSK | 6 | $110 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Novartis | 4 | $72 |
| Bayer | 3 | $60 |
| Eisai Inc. | 2 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Astellas Pharma US Inc | 3 | $51 |
| Tactile Systems Technology Inc | 3 | $41 |
| Inspire Medical Systems, Inc. | 2 | $37 |
| Globus Medical | 1 | $35 |
| MDD US Operations, LLC | 1 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 3 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Harmony Biosciences LLC | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Bioventus LLC | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Abbott | 1 | $16 |
| Novo Nordisk | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Si-bone, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Amgen | 1 | $12 |
How this compares
$2,112 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $101,307 |
| EliquisApixaban | 125 | $83,628 |
| TrulicityDulaglutide | 82 | $79,076 |
| MounjaroTirzepatide | 65 | $74,373 |
| OzempicSemaglutide | 60 | $69,300 |
| JardianceEmpagliflozin | 58 | $56,313 |
| VraylarCariprazine Hcl | 32 | $45,891 |
| XareltoRivaroxaban | 54 | $23,458 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $20,864 |
| MyrbetriqMirabegron | 45 | $20,138 |
| RexultiBrexpiprazole | 13 | $20,102 |
| JanuviaSitagliptin Phosphate | 31 | $19,180 |
| EntrestoSacubitril/Valsartan | 21 | $17,283 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $15,264 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 460 | $13,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $246 | $153,450147 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $19 | $101,30713 claims |
| PfizerEliquis | $198 | $83,628125 claims |
| Novo NordiskOzempic | $16 | $69,30060 claims |
| AbbVieVraylar | $470 | $45,89132 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $110 | $36,12957 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $51 | $25,59256 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $84 | $20,10213 claims |
| NovartisEntresto | $72 | $17,28321 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $151 | $5,07613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Lubbock
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.